Kamada (KMDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.

1 analysts have issued 12-month price targets for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.

Kamada's stock was trading at $4.01 at the beginning of the year. Since then, KMDA shares have increased by 33.2% and is now trading at $5.34.
View the best growth stocks for 2023 here.

Kamada saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 9,400 shares, a decrease of 29.3% from the August 31st total of 13,300 shares. Based on an average daily volume of 26,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.1% of the company's stock are short sold.
View Kamada's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 28th 2023.
View our KMDA earnings forecast.

Kamada Ltd. (NASDAQ:KMDA) announced its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to the consensus estimate of $34.18 million. Kamada had a net margin of 2.35% and a trailing twelve-month return on equity of 7.42%. During the same period in the previous year, the company posted $0.07 earnings per share.

Kamada issued an update on its FY 2023 earnings guidance on Wednesday, August, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMDA stock can currently be purchased for approximately $5.34.

Kamada (NASDAQ:KMDA) has a market capitalization of $239.34 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or $0.08 on an earnings per share basis.

The company employs 380 workers across the globe.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.